The first FDA-approved RAF inhibitor, sorafenib, belongs to the type-II BRAF inhibitors and, in spite of a rather disappointing start, it showed little efficacy against BRAF-mutant melanoma—studies in other cancer types, such as renal cell carcinoma or hepatocellular carcinoma, have revealed a BRAF inhibition-independent antiproliferative and antitumoral effect, therefore the inhibition of tumor growth might be due to inhibition of other kinases [103,104]. Here, BRAF is linked to neoplasm.